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ABSTRACT» The low incidence of coronary heart disease (CHD) in premenopausal women is partly ascribed 
to protection by endogenous estrogen production. As a consequence, we hypothesized that premenopausal 
women with low endogenous estrogen production or high androgen production might be at increased risk for
CHD.
We studied the relationship between urinary sex hormone excretions and CHD risk by means of a nested 
case-referent study within a cohort of premenopausal (ages 40—49 yrs) women (n =  11,284). This cohort was 
formed at a breast cancer screening project in 1982-1986 (The Diagnostisch Onderzoek Mammacarcinoom 
[DOM] Project). Baseline data included self-administered questionnaires and anthropometric measurements. At 
the time of screening the women were instructed to collect an overnight urine sample on day 22 of three separate 
cycles. These urine samples were stored at —20°C. Up to June 1991, 45 subjects were admitted to local hospitals 
on diagnosis of CHD (29 with myocardial infarction, and 16 with angiographically confirmed coronary disease). 
Referents were sampled from the cohort, matched for age and year of screening in a 1:3 ratio. In a follow-up 
study, menopausal state of the subjects was assessed yearly by mailed questionnaires.
Urinary excretions of estrone-glucuronide, pregnanediol-glucuronide, and testosterone-glucuronide adjusted 
by creatinine were similar for cases and referents. Cases had no earlier menopause than referents, although cases 
had more anovulatory cycles.
The occurrence of CHD in middle-aged women is not preceded by a low premenopausal endogenous estrogen 
production or high androgen production. Anovulatory cycles appear more frequently in women who develop
CHD many years later, j c l in  e p id e m io l  5013:275-281, 1997- © 1997 Elsevier Science Inc.
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INTRODUCTION
Endogenous estrogens may protect women from coronary 
heart disease (CHD). Age-standardized CHD mortality ap­
pears to be twice as high in men as in women, and this same 
ratio is observed in countries with substantial differences in 
C H D  mortality rates [1]. Furthermore, the male/female ra­
t io  in CHD mortality declines from about 5 at age thirty to 
less than 2 at age 75 [1,2]. Ovariectomized women have a 
higher CHD risk, unless they receive estrogen replacement 
therapy [3]. Natural menopause changes CHD risk factors 
such as blood pressure and plasma lipoproteins in an unfa­
vorable direction, which can be attenuated by exogenous
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estrogens [1,4]. Finally, post-menopausal estrogen replace­
ment therapy is associated with a 50% lower risk for cardio­
vascular events [5],
The relationship between endogenous estrogens and 
CHD risk has been intensively investigated in men [1]. In 
cross-sectional and case-control studies increased or normal 
plasma estrogen levels were reported in men with CHD [1], 
In two prospective studies no relationship was observed be­
tween CHD and plasma estrogens [6,7]* In women, endoge­
nous sex hormones in relation to CHD risk have been inves­
tigated mainly indirectly' by comparison of reproductive 
histories, including age at menarche, number of pregnan­
cies, age at first delivery, cycle regularity, and age at meno­
pause. High parity and first child birth at an early age has 
been reported to increase the risk [5,8-10]. Interrelation­
ships between reproductive factors and confounding by so­
cial status and pregnancy loss may bias the results of these
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studies [5]. If estrogens protect from CHD, women with low 
endogenous estrogen or high testosterone levels would be 
at higher risk for this disease. This hypothesis was tested in 
a nested case-referent study of urinary sex hormone excre­
tions and CHD risk within a cohort of premenopausal 
women from a breast cancer screening project (The Diag­
nostisch Onderzoek Mammacarcinoom [DOM] Project 
[11]).
METHOD
Study Population and Baseline Data Collection
All women from the city of Utrecht and vicinity, aged 4 0 -  
49, were invited to participate in a research screening pro­
gram for early detection of breast cancer in 1982-1986 (The 
Diagnostisch Onderzoek Mammacarcinoom [DOM] Project
[11]). The response rate was 44% (n =  15,483). Exclusion 
of subjects reporting a history of myocardial infarction (49), 
angina pectoris and taking medication for this (80), current
use of steroid hormones (572), and menopausal status at 
entry (4,199) reduced the number to 10,583, constituting 
the cohort of this study. Participants filled out question­
naires covering medical history, use of medication, smoking 
history, menarche, menstrual cycle, fertility, and pregnan­
cies. Length and weight were measured. Permission was ob­
tained to use the data for future research purposes.
Before examination the women were asked to deliver a 
urine sample, collected overnight on day 22 of three consec­
utive menstrual cycles (thus resulting in three luteal sam­
ples). Women with irregular cycles had to bring a urine sam­
ple at a random day (when the start of the actual cycle could 
not be defined). The women were asked to keep a menstrual 
calendar for at least three months, providing information 
about cycle length and regularity, the exact moment of 
urine collection in the cycle and days of menstrual blood
loss. The women bom in 1942-1945 (n = 2,528) were 
screened in 1985 and 1986 and collected one overnight 
urine sample with no specific notice of the cycle day. All 
urine samples were stored at — 20°C in 250-ml plastic con­
tainers.
Case-Finding
Medical registries of all 10 hospitals within the recruitment 
area of the screening were searched for hospital admit­
tances, with diagnosis codes 410-414 (ICD) [12], of women 
who had originally participated in the screening. Follow-up 
period was until July 1, 1991, one hospital until January 1, 
1990 and two hospitals until January 1, 1991. Medical rec­
ords were reviewed to verify the diagnosis. CHD cases were 
defined as subjects suffering from either acute myocardial 
infarction (n =  29), according to WHO criteria [13], or 
angiographically proven coronary artery disease causing pre­
cordial pain (angina pectoris). A stenosis of >50% in at 
least one of the main coronary arteries had to be present 
(n =  16). Inclusion was decided by a medical doctor and
confirmed by two independent colleagues, a specialist in in­
ternal medicine and a cardiovascular epidemiologist. Only 
subjects, who had their first hospital admittance on basis of 
CHD after the moment of screening, were eligible.
Sampling
Referent subjects were randomly sampled out of the cohort 
(nested case-referent design [14]) and individually matched 
for age (± 6  months) and date of urine storage (± 6  months) 
to cases in a 3:1 ratio. Referent subjects of cases bom in 
1942-1945 were additionally matched for the cycle day of 
urine collection.
Data Collection
Data pertinent to the study aim were selected from the base­
line questionnaire, including prevalence of diabetes and hy­
pertension and smoking habit. Subjects were considered to 
have irregular cycles if the average cycle length of three 
cycles exceeded 35 days or was less than 21 days or if the 
length of separate cycles differed more than 7 days. Eighty- 
three percent of the subjects (only women born in 1932- 
1941) were addressed by means of a yearly questionnaire
to establish the age at menopause. Natural menopause was 
defined as the absence of menstrual bleeding, not surgically 
induced, for at least 12 months.
The urine samples of c^ses and referents were thawed 
overnight at room temperature, homogenized by gentle 
manual shaking and poured out in polystyrene tubes that 
were refrozen at — 20°C. Creatinine concentrations were 
measured by an automated Jaffe reaction using Boehringer 
(Mannheim, Germany) reagents, preceded by centrifuga­
tion (3,000 rpm, 10 min).
Assessment of Steroid Qlucuronides
Concentrations of pregnanediol glucuronide and estrone 
glucuronide were assessed by direct specific radioimmunoas­
says of urine samples diluted 1:1,000. Reagents were ob­
tained from Dr. P. Samarajeewa, Department of Biochemis­
try, University College of London, London, U.K.
The intra-assay coefficient of variation (CV) for preg­
nanediol glucuronide was 31%; 5.2% and 6.7% at concen­
trations of 0.51; 3.1 and 22.7 //mol/1, respectively (n = 20). 
The inter-assay CV was 40% and 10.4%, respectively, at 
0.46 and 22.4 //mol/i. As more than 98% of the results ob­
tained was between 3 and 22.7 //mol/1, the high CV at the 
very low level of 0.5 /¿mol/1 was judged not to influence the 
final outcome. The intra-assay CV for oestrone glucuronide
was 12.8%; 6.9% and 6.3% at concentrations of 0.032;
0.102 and 1.02 //mol/1, respectively (n = 20). The inter­
assay CV was 13.8% and 6.6%, respectively, at 0.040 and
0.938
The concentration of testosterone glucuronide was as­
sessed as testosterone by radioimmunoassay after enzymatic
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hydrolysis of the urine (diluted 1:20) with 032 Units of 
Escherichia coli /7-glucuronidase (Boehringer Mannheim, 
Germany) /50 /A urine for 20 hrs at 37°C. This enzyme 
preparation is sulphatase free. After hydrolysis, the solution 
was neutralized with 50 ju\ sodium hydroxide and extracted 
with 5 volumes diethyl ether. The extracts were evaporated 
to dryness and the residue was dissolved in ethanol. Appro- 
priate aliquots were used for the testosterone radioimmuno­
assay, which was carried out as described before [15]. The
intra-assay CV was 3.5% and 8.8% at 4.6 and 23.8 jumoll
I, respectively, whereas the inter-assay CV was found to be
II.7% and 12.6% at the same levels (n = 10).
Analysis
Statistical procedures for matched data were used. Crude 
analysis was performed with the Wilcoxon test for paired 
data. For this test the matched pairs contain the value of 
the case and the mean value of the corresponding referents 
of the matched set. Hormone excretion per sample was ad­
justed by division by creatinine. The hormone excretion 
level of a subject was computed as the mean of these creati­
nine adjusted values of all available samples per subject. Ad­
justment for potential confounders was performed by condi- 
tional logistic regression. For this analysis, hormone/ 
creatinine ratios were divided in tertiles. Odds ratios were 
computed of second and third tertiles with the first tertile 
as reference. The multivariate models included terms in the 
following form: smoking (nonsmoker, 1-10 cigarettes a day, 
more then 10 cigarettes a day); hypertension (drug treat­
ment yes/no), diabetes mellitus (diet- or drug treatment yes/ 
no); Quetelet Index (continuous); number of days till next 
menstrual bleeding (continuous); cycle regularity (yes/no); 
menarcheal age (continuous); cycle length (continuous); 
and parity (number of live births).
The follow-up of menopausal age was analyzed with sur­
vival analysis. As failure event we defined surgical meno­
pause or the date of last menstrual bleeding followed by a 
period of amenorrhea of at least 12 months. Subjects not 
fullfilling this criterion were censored at the date of the last 
known menstrual bleeding. Furthermore, non-responding 
subjects were censored at the date of screening. Differences 
in curves were tested with the non-parametric Logrank test.
SPSS [16], EGRET [17], and NCSS [18] statistical packages
were used. Urine samples were considered luteal when preg- 
nanediol glucuronide excretion exceeded 0.5 //mol/mmol 
creatinine [19]. For nine out of 468 urine samples hormone 
levels were not determined for reasons of nonretrieval of 
the sample or leaking containers.
RESULTS
The two groups differed significantly in smoking behavior, 
and prevalence of hypertension and diabetes (Table 1). 
None of the reproductive factors like menarcheal age, par­
ity, age at first delivery, menarche till first-childbirth inter­
val, or cycle regularity and cycle length at the time of base­
line, were different between the two groups.
For both cases and referents, characteristics of the distri­
bution of the subjects’ mean estrone-glucuronide/creatinine 
ratio (EG/C), pregnanediol-glucuronide/creatinine ratio 
(PG/C), and testosterone-glucuronide/creatinine ratio 
(TG/C) are shown (Table 1). Figures 1, 2, and 3 show the 
individual values of cases and referents of EG/C, PG/C, and 
TG/C, respectively. No statistical differences at group level
were observed (EG/C: p =  0,83; PG/C: p =  0.09; TG/C: 
p =  0,92; Wilcoxon test).
The third and fourth column in Table 1 present the same 
variables, after exclusion of all nonluteal urine samples
(PG/C <  0,5 juvaol I m m ol). In total, 123 of 457 samples 
(27%) were excluded (36% of cases and 24% of referents). 
For all subjects new mean excretions were counted using 
only the luteal samples. Subjects not having at least one 
urine sample with PG/C >  0.5 /¿mol/mmol, were com­
pletely (for all variables) excluded. By this criterion, sig­
nificantly more cases than referents were excluded because 
of anovulatory cycles (29% versus 14%; p =  0.02). Again 
no differences between cases and referents were observed in
the hormonal parameters (EG/C: p = 0.15; PG/C:p = 0.64; 
TG/C: p =  0.78; Wilcoxon test). In conditional logistic
regression analysis the three hormone/creatinine ratios 
were entered in tertiles, leaving the first (lowest) tertile as 
reference, The crude and smoking adjusted odds ratios for 
the tertiles are shown in Table 2. None of the odds ratios 
was significantly different from 1. Additional adjustment for 
Quetelet Index, hypertension, cycle regularity, parity, and 
number of days till next menstrual blood loss did not result 
in substantially different odds ratios.
Follow-up of Age at Menopause
Kaplan-Meier survival curves for both cases and referents, 
with menopause as defined endpoint, were equal (p =  0.4, 
logrank test) (Fig. 4). The median menopausal age was 52.3 
(interquartile range 50.3-53.7) for referents and 53.3 (in­
terquartile range 51.3—54*8) for cases, Earlier menopause 
was observed among smokers (yes/no, p = 0-02), subjects 
with irregular cycles (p =  0.01). (Subjects with nonovuta- 
tory cycles: p =  0,07).
DISCUSSION
Urinary excretions of sex hormones and subsequent risk of 
CHD were not related in this prospective study among pre­
menopausal women. Consequently the hypothesis that low 
endogenous estrogen production, or high production of an­
drogens, may render premenopausal women at increased 
risk for CHD could not be confirmed. The use of urinary 
excretions of steroid sex hormones is valid, as these are rep­
resentative of plasma levels of these hormones [20].
The higher prevalence of anovulatory cycles in cases 
could suggest an association of CHD risk with early meno-
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TABLE 1. Nested case-referent study of urinary sex hormone excretions in premenopausal women and coronary heart disease 
risk
Total Non-luteal samples excluded
Cases Referents Cases Referents
n 45 135 32 (71%“) 116 (86%)
Age (years) 45.6 (3.2) 45.7 (3.2) 45.4 (3) 45.8 (3.1)
Year of investigation 1984.2 (1.1) 1984.2 (1.1) 1984 (1.0) 1984 (1.0)
Body mass index (kg/m)2 25.2 (3.3) 24.3 (3.7) 25.4 (3.6) 24.3 (3.9)
Smoking (% yes)1’ 60 38 59 38
Hypertension (% yes)b 24 11 25 11
Diabetes (% yes)b 7 0 2 0
Menarcheal age (years) 13.4 (1.6) 13.5 (1.5) 13.2 (1.2) 13.5 (1.4)
Childless (% yes) 4 15 3 14
Parity 2.4 (1.2) 2.5 (1.7) 2.3 (1.1) 2.5 (1.4)
Age at first delivery0 25.0 (3.7) 25.1 (3.3) 25.4 (3.0) 25.2 (3.2)
Time from menarche to first deliveryc 11.7 (3.4) 11.6 (3.3) 12.2 (3.3) 11.7 (3.3)
Subjects with regular cycles (%) 65 75 71 76
Average cycle length (days)*1 26.0 (2.3) 26.8 (2.3) 26.4 (1.9) 26.6 (2.3)
Estrone-glue, /creatinine 0.021 (0.002)" 0.019 (0.001)' 0.024 (0.002)" 0.019 (0.001)'
50th percentile 0.018 0.017 0.019 0.017
Pregnanediole-gluc./creatinine 0.877 (0.090)' 1.018 (0.052)“ 1.270 (0.084)" 1.238 (0.050)'
50 th percentile 0.83 0.89 1.24 1.12
T estosterone-gluc./creatinine 3.247 (0.331)" 3.014 (0.141)" 3.436 (0.460)" 3.004 (0.155)'
50th percentile 2.52 2.62 2.46 2.59
Baseline characteristics from cases and referents. The first two columns present data from all subjects (total group), the third and fourth columns present 
data from subjects with at least one luteal sample (pregnanediol'glucuronide/creatinine ratio ^  0.5 //mol/mmol). Urine samples from DOM Cohort, Utrecht, 
Netherlands, collectcd in 1982-1986. Categorical data are expressed in percentages. Continuous variables are expressed in mean (SD).
"Difference cases - referents p = 0.02.
^Difference cases - referents p <  0.05. 
l'Of parous women only.
^Of women with regular cycle lengths only.
CSE.
pause [19]. However, with follow-up of menopausal age, no 
difference in time interval between baseline and menopause 
was observed between cases and referents, despite this 
higher prevalence of anovulatory cycles and smoking among 
cases. As smoking and prevalence of anovulatory cycles in 
this study were not related the occurrence and frequency of
anovulatory cycles may independently indicate CHD risk 
rather than levels of hormone excretions measured in the 
luteal phase of ovulatory cycles. This was supported by sepa- 
rate analysis of the samples with a pregnanediolglucuronide/ 
creatinine ratio ^ 0 ,5  //mol/mmol, a criterion for recent 
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FIGURE 1. Estrone-glucuro- 
nide/creatinine ratio (individ* 
ual values for cases and con«* 
trols). Nested case-referent 
study of urinary sex hormone 
excretions in premenopausal 
women and CHD risk. Scat- 
terplot of estrone-glu- 
curonide/creatinine ratio dis­
tribution. Urine samples from 
DOM Cohort, Utrecht, Netlv 
erlands, collected in 1982- 
1986. Abbreviation: EG/C-es- 
trone-glucuronide/creatinine 
(¿tmol/mmol).
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FIGURE 2. Pregnanediol-glu- 
curonide/creatin ratio (in­
dividual values for cases and 
controls). Nested case-refer- 
ent study of urinary sex hor­
mone excretions in premeno­
pausal women and CHD risk. 
Scatterplot of pregnanediol- 
glucuronide/creatinine ratio 
distribution. Urine samples 












FIGURE 3. Testosterone-glu- 
curonide/creatinine ratio 
{individual values for cases 
and controls). Nested case- 
referent study of urinary sex 
hormone excretions in pre­
menopausal women and CHD 
risk. Scatterplot of testos- 
teron-glucuronide/ creatinine 
ratio distribution. Urine sam­
ples from DOM Cohort, 
Utrecht, Netherlands, col­





























Crude 0.8 1.6 1.0 13 0.6 0.9
(0.2-2.5) (0.6-4.2) (0.4-2.8) (0.5-3.4) (0.2-1.7) (0.3-2.4)
Adjusted for 0.7 1.8 0.9 1.3 0.6 0.6
smoking (0.2-2.4) (0.7-4.7) (0.3-2.6) (0.4-3.7) (0.2-1.7) (0.2-1.7)
Odds ratios (and 95% confidence intervals) of coronary disease of second and third tertiles of classification for hormone/creatinine ratio, with the first 
(lowest) tertile as reference. All non-luteal samples were excluded. Urine samples from DOM Cohort, U trecht, Netherlands, collected in 1982-1986.
of hormone excretions and CHD was present. Whether 
these findings suggest that the hormonal interactions associ­
ated with ovulation protect against coronary heart disease 
is of interest.
The findings from the present study are in accordance 
with results of hormone studies in men, indicating no rela­
tion of endogenous estrogen plasma levels and CHD risk in 
men. In prospective studies in men plasma estradiol levels
in CHD cases were similar to controls [6,7]. Estrogen levels 
tend to increase after a myocardial infarction [1],
It is unlikely that inaccurate urine sampling and storage 
times would have obscured potential differences. The 
women had been instructed to collect the urine samples on 
day 22 of a cycle. Differences in cycle length resulted in 
variation of the urine collection time to the ovulation. Ad­
justment for differences in cycle length by “time until next








cholesterolemia, similar to other “classical” risk factors as 
smoking, hypertension, and diabetes, with development of 
CHD in this cohort of women at premenopausal age.
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FIGURE 4. Nested case-referent study of urinary sex hor­
mone excretions in premenopausal women and CHD risk. 
Age at menopause for cases (dottedline) and referents (solid 
line), Kaplan-Meier curves with menopause as endpoint. 
DOM Cohort, Utrecht, Netherlands.
Difference between cases and referents: p  = 0.4, Log-rank 
test.
menstrual bleeding,” accounting for the more time constant 
luteal phase instead of the follicular phase, did not have a 
substantial effect on the odds ratios. The long duration of 
frozen storage is not a likely explanation for loss of differ­
ences, as steroid hormones are known to be stable under 
these conditions. Moreover, storage conditions were identi­
cal in cases and referents.
Of the reproductive factors, high parity, first childbirth 
at age < 2 0  years have been related to coronary heart disease 
[5,8,9], but the reports are contradictory. In our study these 
factors did not predict coronary heart disease. Odds ratios 
for high parity and for young age at first childbirth were <1, 
but the 95% confidence intervals were wide as a result of 
the low power of this study to find associations for these 
factors. The median age for menopause was high for both 
cases and referents (52.3 and 53,3, respectively) [21], proba­
bly affected by the study design, excluding women being 
postmenopausal at entry. Therefore, the study does not 
allow conclusions on the relationship between age of meno­
pause and subsequent cardiovascular disease risk.
Exogenous estrogen use as hormone replacement therapy 
(HRT) is associated with lower coronary disease incidence 
[5]. However, whether this association is causal is not yet 
clear. Furthermore, exogenous estrogens may influence cor­
onary disease risk in a different way compared to endoge­
nous estrogens.
Plasma samples were not prospectively collected in this 
cohort precluding case-control comparisons. Information 
on cholesterol values traced from the hospital records in 
87% of cases indicated that 75% had a plasma cholesterol 
value > 6 .0  mmol/1, indicating a strong association of hyper­
CONCLUSION
Premenopausal women at higher risk of coronary heart dis­
ease could not be identified by means of measurement of 
urinary sex hormone excretions. The results of this study 
are congruent with findings in men, where gradual differ­
ences in endogenous estrogen levels do not predict coronary 
heart disease risk. The relatively high frequency of anovula­
tory cycles in women who will develop CHD is of interest 
as it suggests a relationship of CHD with ovulation.
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